The Journal of Pediatrics
Volume 155, Issue 5 , Page 763 , November 2009

Indomethacin and retinopathy of prematurity

References 

  1. Jegatheesan P, Ianus V, Buchh B, Yoon G, Chorne N, Esing A, et al. Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: a multicenter, randomized, controlled trial. J Pediatr. 2008;153:183–189
  2. Hammerman C. Indomethacin and retinopathy of prematurity: the hidden paradox. J Pediatr. 2008;153:587–588
  3. Darlow BA. Incidence of retinopathy of prematurity in New Zealand. Arch Dis Child. 1988;63:1083–1086
  4. Darlow BA, Horwood LJ, Clemett RS. Retinopathy of prematurity: risk factors in a prospective population-based study. Paediatr Perinat Epidemiol. 1992;6:62–80
  5. Van Bel F, Van de Bor M, Stijnen T, Baan J, Ruys JH. Cerebral blood flow velocity changes after a single dose of indomethacin: duration of its effects. Pediatrics. 1989;84:802–807
  6. Edwards AD, Wyatt JS, Richardson C, Potter A, Cope M, Delpy DT, et al. Effects of indomethacin on cerebral haemodynamics in very preterm infants. Lancet. 1990;335:1491–1495
  7. Laughon M, Bose C, Clark R. Treatment strategies to prevent or close a patent ductus arteriosus in preterm infants and outcome. J Perinatol. 2007;27:164–170

PII: S0022-3476(09)00544-7

doi: 10.1016/j.jpeds.2009.05.038

The Journal of Pediatrics
Volume 155, Issue 5 , Page 763 , November 2009

Article Tools